Cancer
Decades after a small breast cancer vaccine trial, researchers link lasting immune memory to CD27
An Ruwaito ta hanyar AI Hoton da AI ya samar An Binciki Gaskiya
More than 20 years after a small Duke-led clinical trial tested an experimental breast cancer vaccine, Duke Health says all participating women are still alive—an outcome researchers describe as unusual for metastatic disease. Follow-up analyses found long-lived immune cells marked by CD27, and mouse experiments suggest that stimulating CD27 can boost vaccine-driven tumor control.
In an op-ed in Le Monde, Philippe Bergerot, president of the Ligue contre le cancer, criticizes the state's focus on curative care and advocates for local action in prevention ahead of municipal elections and World Cancer Day on February 4.
An Ruwaito ta hanyar AI
A randomized trial shows that administering cancer immunotherapy before 3pm can nearly double survival time for patients with non-small cell lung cancer. Researchers found significant benefits from aligning treatment with circadian rhythms during the initial cycles. This marks the strongest evidence yet for chronotherapy in oncology.
Scientists at Moffitt Cancer Center report developing a computational method, ALFA-K, that uses longitudinal single-cell measurements to infer how gains and losses of whole chromosomes can shape a tumor’s evolutionary path. The work, published in Nature Communications, argues that these large-scale chromosome changes follow measurable patterns influenced by cellular context and treatment-related stress rather than unfolding as pure randomness.
An Ruwaito ta hanyar AI
A new study reveals that chemotherapy's damage to the gut lining unexpectedly rewires the microbiota, producing a compound that strengthens immune defenses against cancer spread. This process reduces immunosuppressive cells and enhances resistance to metastasis, particularly in the liver. Patient data links higher levels of this compound to improved survival in colorectal cancer cases.
Researchers have discovered that a byproduct of vitamin A, all-trans retinoic acid, weakens the immune system's fight against cancer and reduces the effectiveness of certain vaccines. In preclinical studies, a new drug called KyA33 blocks this pathway, enhancing immune responses and slowing tumor growth. The findings, from two studies, explain a long-standing paradox about vitamin A's role in cancer.
An Ruwaito ta hanyar AI
Scientists at Northwestern Medicine have developed an antibody that counters pancreatic cancer's sugar-based disguise, enabling the immune system to attack tumors more effectively. In mouse studies, the therapy slowed tumor growth by restoring immune activity. The team is preparing the antibody for human trials.
Scientists identify periostin's role in pancreatic cancer spread
January 30, 2026 01:07Mount Sinai researchers report Trojan horse CAR T approach that targets tumor macrophages in mouse models
January 29, 2026 16:06Faecal transplants enhance kidney cancer treatment results
January 29, 2026 15:53Long-term heavy alcohol use raises rectal cancer risk
January 29, 2026 00:09Researchers develop nanoparticles to target disease proteins
January 20, 2026 23:46Ibuprofen linked to lower endometrial cancer risk
January 20, 2026 03:55UBC researchers show how to reliably generate helper T cells from stem cells by tuning Notch signaling
January 19, 2026 11:12Breast cancer disrupts brain rhythms early in mice
January 17, 2026 22:12Dave Mustaine to release memoir during Megadeth's farewell tour
January 17, 2026 13:01Delhi high court allows cheaper cancer drug in India